LncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer. (31st July 2019)

• Record Type: Journal Article
• Authors: Liu, Hong Yue; Lu, Sheng Rong; Guo, Zi Han; Zhang, Zhi Sheng; Ye, Xuan; Du, Qiong; Li, Huan; Wu, Qiang; Yu, Bo; Zhai, Qing; Liu, Jin Long
• Is Part Of: Journal of investigative medicine. Volume 68:Number 1(2020)
• Page Start: 52
• Page End: 59
• Publication Date: 2019-07-31
• Subjects: non-small cell lung cancer -- SLC16A1-AS1 -- proliferation -- prognosis; Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.1136/jim-2019-001080
• Languages: English
• ISSNs: 1081-5589

Abstract

Abstract : Long non-coding RNAs (lncRNAs) have proved to act as crucial biomarkers in tumors. Novel biomarkers in non-small cell lung cancer (NSCLC) need to be investigated badly. To identify the differentially expressed lncRNAs between NSCLC tissue and adjacent tissue, microarray analysis was performed. lncRNA SLC16A1-AS1 was significantly less expressed in NSCLC tissue than that in adjacent tissue. Gain-of-function experiments was performed to determine the biological functions of SLC16A1-AS. In situhybridization and survival analysis were applied in lung cancer tissue samples to determine the prognostic role of SLC16A1-AS1. It was showed that SLC16A1-AS1 was remarkably downregulated in NSCLC tissues and cell lines. Functionally, SLC16A1-AS1 overexpression could inhibit the viability and proliferation of lung cancer cell, block the cell cycle and promote cell apoptosis in vitro which may result from reduced phosphorylation of rat sarcoma (RAS)/ proto-oncogene serine/threonine-protein kinase (RAF)/ mitogen-activated protein kinase kinase (MEK)/ extracellular regulated protein kinases (ERK) pathway caused by elevated expression of SLC16A1-AS1. Clinical sample analysis showed that SLC16A1-AS1 had a favorable impact on the overall survival and progression-free survival of patients with NSCLC. Our results suggested that SLC16A1-AS1 may act as a potential biomarker for patients with NSCLC.